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Abstract
Several animal models have been established to study visceral leishmaniosis (VL), a worldwide vector-borne disease
affecting humans and domestic animals that constitutes a serious public health problem. BALB/c mice and Syrian
hamsters are the most widely used experimental models. In this paper, we summarize the advantages and
disadvantages of these two experimental models and discuss the results obtained using these models in different
studies of VL. Studies using the BALB/c mouse model have underscored differences between the liver and spleen
in the course of VL, indicating that pathological evaluation of the visceral organs is essential for understanding the
immune mechanisms induced by Leishmania infantum infection. The main goal of this review is to collate the
relevant literature on Leishmania pathogenesis into a sequence of events, providing a schematic view of the main
components of adaptive and innate immunity in the liver and spleen after experimental infection with L. infantum
or L. donovani. This review also presents several viewpoints and reflections about some controversial aspects of
Leishmania research, including the choice of experimental model, route of administration, inoculum size and the
relevance of pathology (intimately linked to parasite persistence): a thorough understanding of which is essential
for future VL research and the successful development of efficient control strategies for Leishmania spp.
1. Introduction
The parasitic protozoa of the genus Leishmania cause a
spectrum of diseases in humans, ranging from subclini-
cal cutaneous infections to more serious disseminating
diffuse cutaneous, mucocutaneous and visceral forms of
the disease. Leishmaniosis is one of the most prevalent
neglected tropical diseases affecting public health world-
wide [1,2]. It is transmitted by the bite of female sand-
flies. In developing countries it is associated with
extreme poverty. It is estimated that at least 20 million
people are infected with Leishmania. The visceral form
is the most severe form of the disease. Annually, there
are approximately 500 000 new cases of visceral leish-
maniosis (VL) [3]. Leishmania donovani is the primary
cause of VL in the Indian subcontinent and East Africa,
L. infantum in the areas surrounding the Mediterranean
S e aw h e r ei ti saz o o n o s i s ,a n dL. chagasi in the New
World. The last two species are identical. Human beings
are the only known reservoir of L. donovani,w h i l e
canines provide the reservoir for L. infantum and
L. chagasi [4]. However, since asymptomatic parasitemic
injecting drug users who share injecting devices seem to
be a suitable reservoir for Li n f a n t u m , an artificial
anthro-ponotic cycle would be completed. Needles and
syringes would be the vectors and uninfected injecting
drug users the receptors [5]. Also, L. infantum is known
to cause opportunistic infections in patients with HIV/
AIDS [6]. Canis familiaris is the major host for these
parasites, and the main reservoir for human visceral
infection [7]. The risk for reintroduction of VL and
other vector-borne diseases in Europe as a consequence
of global warming has recently been highlighted [8].
Indeed, VL appears not to be limited to the Mediterra-
nean region and has now spread northwards [9].
Manifestations of VL can vary from asymptomatic
infection to progressive fatal visceral disease. Disease
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mania involved and the genetics and immune status of
the host. Active VL is characterized by fever, weight
loss, hypergammaglobulinemia, hepatosplenomegaly,
anemia, thrombocytopenia, leukopenia and immunode-
pression [10,11]. Also, the presence of parasite-specific
antibodies forming immune complexes in the kidneys
may lead to the development of glomerulonephritis
[12,13].
Leishmaniosis diagnosis and treatment are expensive.
Despite considerable advances, there are still no efficient
vaccines available against human leishmaniosis [14,15].
Recently, a vaccine containing the fucose-mannose
ligand has been industrialized and licensed for commer-
cialization in Brazilian endemic areas under the name of
Leishmune
® (Fort Dodge Ltda, São Paulo, Brazil) to pre-
vent canine VL. Unfortunately, the immune response
induced by vaccination has not yet been fully investi-
gated. Also, this vaccine is solely recommended for
asymptomatic and seronegative dogs [16-19].
L. infantum has a digenetic life-cycle (Figure 1), alter-
nating between free-living, flagellated, promastigotes in
phlebotomine sand flies and obligate, intracellular, afla-
gellated amastigotes, which preferentially multiply within
macrophages or dendritic cells (DCs) of the vertebrate
host [20,21].
Several experimental models of VL have been devel-
oped, but none of these entirely reproduce the disease
in humans [22]. Much of the literature from these mod-
els documents the immune parameters contributing to
resistance against the visceralizing Leishmania species
used in vaccine studies [23]. This contrasts with a lim-
ited number of studies which have been prompted to
study pathological aspects related to VL. In this context,
close attention should be given to the histopathological
alterations. Humans, dogs and hamsters often exhibit
severe clinical signs and symptoms during visceral infec-
tion [23-25], whereas mice generally show a few minor
signs or no clinical signs at all, depending mainly on the
size of the parasite inoculum [26]. Under experimental
conditions, progression of visceral disease also depends
on the route of infection together with the strain of
Leishmania parasites used [22]. These factors make the
choice of a suitable laboratory model difficult. Studies
using experimental murine models of VL do not allow
exact extrapolations to be made concerning susceptibil-
ity in dogs and humans, but increase the ease of identi-
fying genes and predicting their functional roles, as well
as investigating the immune mechanisms involved in
human and canine leishmaniosis. This review will aim
to provide a better understanding of a variety of patho-
logical-immune responses that have been described to
date in the most widely used experimental models of VL
(Syrian hamsters and BALB/c mice). Combining
research approaches at the immunological, pathological
and genetic levels helps to advance our understanding
of the mechanisms involved in visceral infection at dif-
ferent stages of the disease.
2. Syrian hamster model of VL: suitability of this
experimental model
The usual routes of infection in the hamster model of
VL are intracardiac and intraperitoneal. However, the
administration of parasitesb yt h es a p h e n o u sv e i ni n
order to minimize stress on the hamsters has also been
reported [27]. Experimental studies in L. infantum and
L. donovani-infected Syrian hamsters (Mesocricetus aur-
atus) often reveal several clinical signs of progressive VL
(hypergammaglobulinemia, hepatosplenomegaly, anemia,
cachexia and immunodepression) that closely mimic
active canine and human disease [22,23,25,28,29]. Sur-
prisingly, there are significant amounts of Th1 cytokines
(IFN-g, IL-2 and TNF-a) in the spleen, but there is little
or no IL-4. However, to allow the parasites to multiply,
deactivating Th2 cytokines (TGF-b and IL-10) may act
on infected macrophages as well as anti-Leishmania
antibodies (which have no protective role in leishmanio-
sis) that opsonize amastigotes and induce IL-10 produc-
tion in macrophages. These high activation and
deactivation processes are likely to occur mainly in the
spleen and liver [30]. Interestingly, Syrian hamsters exhi-
bit reduced expression of the gene encoding inducible
nitric oxide synthase (iNOS) in response to IFN-g,a n d
this is thought to lead to a low nitric oxide (NO) gen-
eration, subsequently defaulting in parasite killing
[10,28,31]. Furthermore, there is a lack of reagents for
immunological analysis in the hamster model of VL.
Taking these factors into account, we consider the Syr-
ian hamster to be a suitable experimental model for the
study of the pathological features of active VL (as
described below), but it is not a suitable model for the
evaluation of immunization strategies, as a result of the
animal’s high innate susceptibility.
In Syrian hamsters, manifestations of VL can range
from asymptomatic and oligosymptomatic infections to
progressive fatal visceral disease [28]. The pathological
features reported during VL include hypoplasia of the
white pulp in the spleen, hepatic granulomas and the
deposition of a secondary amyloid substance both in the
spleen and the liver [32,33]. Also, other studies of active
VL have reported that infected hamsters develop glo-
merulonephritis associated with deposition of immuno-
globulins and parasite antigens (immune complexes) in
the kidneys. Finally, the disseminated amyloidosis and
glomerulonephritis produce renal failure and nephrotic
syndrome in infected hamsters [12,34]. The visceral
infection in hamsters also induces pathological altera-
tions in hepatocytes, mainly in the endomembrane
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disturbance of liver metabolism [35]. In a recent study
[36], hamsters infected with L. infantum were shown to
develop analogous inflammatory myopathies to those
observed in naturally infected dogs [37]. Taken together,
all these factors probably contributed to the immune
response disorders that resulted in the death of the ani-
mals [22,33].
Pathological studies from our laboratory showed that
after L. infantum intracardiac infection, hamsters exhibited
severe histopathological alterations in both the spleen and
liver at the peak of parasite burden. Among these altera-
tions, we detected the apparition of granulomas in differ-
ent maturation stages and giant cell granulomas with
amastigotes in the liver (Figure 2A-D), as well as
disruption of the splenic architecture accompanied by
lymphoid depletion (Figure 2E-F). Interestingly, several
months after intracardiac infection with 10
7 promastigotes
of L. infantum, we found external mucocutaneous lesions
localized in the snout, accompanied by ulcers on the back
of the animals (Figure 3).
3. Mouse model of VL: genetic control of
susceptibility to L. infantum infection
Genetic control studies of various host defense mechan-
isms in the mouse (Mus musculus) model during the
course of progressive infection with visceralizing Leish-
mania spp. are summarized in Table 1. These experi-
ments made an important contribution in identifying
genes involved in VL innate and acquired immunity.
Figure 1 L. infantum life cycle. (1) During the bloodmeal from an infected vertebrate host, the female sandfly ingests free amastigotes, as well
as intracellular amastigotes. In the midgut of the sandfly the amastigotes transform into procyclic promastigotes. (2) The procyclic promastigotes
multiply and transform into metacyclic promastigotes, the infective stage, that migrate towards the buccal cavity of the sandfly. (3) A bite from
the sandfly transmits Leishmania promastigotes to susceptible mammalian hosts (i.e., humans and dogs). (4) Promastigotes invade macrophages
and DCs. Within these host cells, promastigotes transform into intracellular amastigotes and replicate to produce a large number of parasites. (5)
Consequently, the infected cell ruptures and releases amastigotes into the circulation. (6) Free amastigotes can infect other mononuclear
phagocytic cells of the blood, spleen, liver, lymph nodes and bone marrow, and the life cycle is repeated.
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Page 3 of 13Figure 2 Liver and spleen histological sections from Syrian hamsters stained with H&E. (A) Uninfected hamsters show normal liver
histological sections (×40). (B) Hamsters infected with 10
5 L. infantum parasites show granuloma reactions after three months pi (×40). Compare
(A) with (B). (C) Granuloma formation. Initial parasitization of KCs (arrows) surrounded by a few inflammatory cells (lymphocytes and monocytes),
showing the lack of organization after three months pi (×400). (D) Developing granuloma and giant cells containing few residual amastigotes
after three months pi (×400). (E) Normal splenic architecture in control hamsters (×40). (F) Disruption of the splenic architecture accompanied
with lymphoid depletion in hamsters infected with 10
7 L. infantum promastigotes after three months pi (×40). Compare (E) with (F). Hamsters
and BALB/c mice were purchased from Harlan Interfauna Ibérica S.A. (Barcelona, Spain). The animals were maintained under conventional
conditions approved by the Ethical Committee for the Animal Experimentation of the Complutense University of Madrid.
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ing of the susceptibility at early stages of infection in
BALB/c mice, which reflects the strength of the innate
immune response in controlling early parasite growth
independently of acquired immune mechanisms. The
Slc11a gene also controls susceptibility to bacteria.
Indeed, mutations in Slc11a1 cause susceptibility to
infection with Salmonella spp. [38] and Mycobacteria
spp. [39]. Interestingly, iron is required for replication of
pathogens such as Leishmania parasites in phagosomes.
The Slc11a1 gene encodes a protein expressed on the
membrane of infected phagosomes that removes Fe
2+
and Mn
2+ ions from the intra-phagosomal compartment
restricting intracellular Leishmania multiplication in
iron-limited intracellular environments [40,41]. Geneti-
cally resistant mouse strains (e.g., CBA) possess a func-
tional Slc11a1 gene which confers innate resistance to
early Leishmania parasite growth. In contrast, suscepti-
ble mice strains (e.g., C57BL/6 and BALB/c) possess a
non-functional Slc11a1 gene and early parasite growth
in the liver cannot be controlled [42]. However, most
susceptible mouse strains, including BALB/c, develop
acquired immune mechanisms to control hepatic para-
site growth at later stages of infection (as previously
reviewed [43,44]).
The parasite load in the liver at later stages of infection,
which probably reflects the strength of the acquired
immune response, was found to be controlled by the H2
and Ir2 loci. The haplotype at the H2 genomic region on
chromosome 17 is involved in antigen presentation
through the major histocompatibility complex (MHC).
Genetic polymorphism in the MHC influences the
response to numerous antigens. Several MHC haplotypes
have not only been associated with resistance to leishma-
niosis, but also with resistance to many other infections
[45]. Differences between the H-2
b and H-2
d haplotypes
were observed in the BALB/c background, where H-2
b
resulted in lower parasite numbers in the liver than H-2
d.
In addition to the liver, the H2 region influences parasite
numbers in the spleen and bone marrow [43]. Histo-
pathological analysis revealed that the Ir2 locus in mice
promoted fewer granulomas that were smaller in size,
due to an efficient anti-parasite response.
The parasite burden in the spleen was also found to
be controlled by the Lyst/Beige gene on chromosome
13. Indeed, homozygous C57BL/6J bg/bg (beige) mice
expressed deficient natural killer (NK) cell activity and
failed to eliminate L. donovani amastigotes [46].
4. BALB/c mouse model of VL: organ-specific
immune responses
The variations in the susceptibility to VL in different
strains of mice were first described nearly 40 years
ago [47]. In BALB/c mice, the immune response to
Figure 3 External lesions observed in Syrian hamsters infected with 10
7 L. infantum promastigotes at seven months pi.( A - B )
Mucocutaneous lesions localized in the snout. (C) Ulcers on the back of the hamsters. The isolate M/CAN/ES/96/BCN150 (zymodeme MON-1) of
L. infantum was used for infection experiments. This strain was maintained in our laboratory by passage in Syrian hamsters.
Table 1 Genes that control the immune response to L. donovani/L. infantum infection
Host defense mechanism(s) Locus or gene Chromosome Reference(s)
Innate intraphagosomal control of infection in the spleen and the liver Slc11a1 1 [40-44]
Influences antigen presentation during the acquired immune response in the splen, the liver
and the bone marrow
H2 17 [43,45]
Formation of hepatic granulomas. Acquired immune response Ir2 2 [43]
Influences resistance to parasites in the spleen. C57BL/6J bg/bg mice expressed deficient
natural killer cell activity and failed to eliminate L. donovani amastigotes
Lyst/Beige 13 [46]
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edly between different organs (liver and spleen) within
the same animal. In the liver, the infection can resolve
with subsequent immunity to re-infection, whereas in
the spleen, Leishmania parasites can persist [48]. A
schematic view of the organ-specific immune responses
after experimental infection with L. infantum in suscep-
tible BALB/c mice is shown in Figures 4 and 6.
4.1. Liver: control of hepatic infection
4.1.1. Development of an immune response to the early
stage of infection
After being inoculated into the lateral vein of the tail,
the parasites enter the liver via the portal vein and
invade macrophages and DCs. In both these types of
host cell, promastigotes transform into amastigotes. At
this point, the innate immune system constitutes its first
line of defence against Leishmania parasites. The parasi-
tized resident macrophages (Kupffer cells, KCs) secrete
chemokines (CCL3, CCL2 and CXCL10) that stimulate
the recruitment of monocytes and granulocytes [44].
Despite the activation of these mechanisms in mice,
amastigotes survive during the hepatic acute phase (up
to two weeks post-infection (pi)) in an environment
with small quantities of inflammatory cytokines, in the
absence of activated T cells. Consequently, the number
of parasites in the liver reaches a peak (Figure 4A).
Nevertheless, the parasite burden may decrease dramati-
cally with the acquisition of the granulomatous response
during the next stage of infection, as described below.
4.1.2. Development of an immune response to the later
stage of infection: granuloma formation
Recent research favours a model in which Leishmania-
specific T lymphocytes are pre-activated in the spleen
and then migrate to the liver [48]. Once there, activated
T cells interact with parasitized DCs, serving as a critical
source of IL-12 production, that then triggers the subse-
quent Leishmania-specific CD4
+ Th1 effector response
during the later stage of infection [21]. Interestingly,
activated DCs can also trigger NK cell cytotoxicity and
the production of IFN-g [ 4 9 ] .I nc o n t r a s tt oD C s ,t h e
production of IL-12 is blocked in infected macrophages.
Consequently, the parasite-carrying macrophages are
incompetent at priming CD4
+ T cells or stimulating
antigen-specific CD4
+ T cells [50]. Therefore, the inter-
action of Leishmania-specific CD4
+ T cells with infected
DCs in the liver provides the proinflammatory (Th1)
environment required for efficient granuloma formation
(Figure 4B), which includes IL-12, IFN-g,T N F - a and
IL-2 production [10,48,51-53]. It is at this stage of infec-
tion (weeks 2-4 pi) that the acquired hepatic immune
response is initiated. Simultaneously, the fusion of
infected KCs to form multinucleated cells also contri-
butes to inflammatory cytokine production during
granuloma formation [54,55]. In BALB/c mice, acquired
hepatic resistance to L. infantum clearly depends upon
granuloma development. Thus, the structure of a mature
tissue granuloma consists of a core of fused, parasitized
KCs with an encircling mononuclear cell mantle con-
taining blood monocytes and both CD4
+ and CD8
+ T
cells. In some instances, B cells, plasma cells and granu-
locytes are also attracted. In immunologically active
granulomas, antigen-presenting DCs and cytokine-
secreting T cells are required for antimicrobial activity
[54]. The formation of a granuloma is not always asso-
ciated with parasite control, and the effectiveness of
hepatic granulomas to kill parasites depends on their
degree of maturation [52,54]. It appears that the TNF
family of cytokines are not involved in the formation of
granulomas but instead are involved in their maturation,
as well as the maintenance of splenic architecture [42].
Granulomas become fully evolved by 2-4 weeks pi.
The overall antimicrobial efficacy of the granulomatous
response appears to be variable, and only mature granu-
lomas develop efficient leishmanicidal mechanisms to
kill parasites. In contrast, developing granulomas have
been reported to be less efficient at killing Leishmania
parasites. Among other factors, granuloma development
has been found to vary depending on the initial inocu-
lum size. Indeed, higher numbers of mature and sterile
granulomas are observed in mice infected with a
low-inoculum size than in those infected with a high-
inoculum size [26]. In structurally mature hepatic
granulomas, the elaboration of leishmanicidal reactive
oxygen intermediates (ROIs) and reactive nitrogen inter-
mediates (RNIs) is essential for parasite killing within
infected KCs and DCs [44,54].
There are various classification schemes for granulo-
matous inflammation in VL. Murray et al. [54] reported
a summary of liver granuloma structure-function rela-
tionships in experimental VL. To score the progression
of the granulomatous response, Stager et al. [56] also
classified the infected focus as follows: (1) an infected
KC with no associated cellular infiltrate, (2) an early
granuloma comprising an infected KC surrounded by
a few inflammatory cells, with no organization, (3) a
mature granuloma with an organized structure, or (4) a
sterile granuloma, in which amastigotes had been killed
as a result of effective antileishmanial immunity. Follow-
ing the above criteria our laboratory data also revealed
that the resolution of disease in the livers of mice
infected with L. infantum correlates with granuloma
development (Figure 4C and Figure 5A). Early in the
course of infection, granulomas at various stages of
maturation are apparent [44]. Thus, relatively mature
granulomas can be readily detected alongside infected
KCs that have no associated cellular infiltrate at around
four weeks pi (Figure 4C). Infected KCs exhibiting no
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Page 6 of 13Figure 4 A schematic view of the immune responses in BALB/c mice livers after experimental infection with L. infantum.A f t e r
intravenous inoculation, the parasites enter the liver and invade macrophages and DCs. (A) During the hepatic acute phase (up to two weeks
pi), Leishmania amastigotes multiply in the absence of both IL-12 production and activated T-cells. Consequently, the number of parasites in the
liver reaches a peak. (B) Two weeks pi, Leishmania-specific T lymphocytes migrate to the liver from the spleen and the acquired hepatic immune
response is initiated. The interaction of Leishmania-specific T cells with infected KCs and DCs provides the proinflammatory (Th1) environment
required for efficient granuloma formation, resulting in the resolution of hepatic infection. (C) The kinetics of parasite burden and different stages
of granuloma maturation in the liver after L. infantum infection. Infected KCs with no granulomatous reaction and immature granulomas were
observed in high numbers at 14 days pi but these initial stages of granuloma formation decreased in number during the course of infection,
developing mature and sterile granulomas. Significantly, by 56 days pi, the number of sterile granulomas, in which the amastigotes were killed,
increased and consequently, the Leishmania parasite burden decreased. Finally, the infection in the liver of BALB/c mice was resolved.
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(Figure 5B) were observed in high numbers at two
weeks pi, but their numbers decreased during the course
of infection as mature (Figure 5C), sterile (Figure 5D)
granulomas developed, in which the amastigotes were
killed. After eight weeks pi, sterile granulomas gradually
dissembled in an involution process [54]. Although ster-
ile cure is never achieved in the liver, parasite growth is
controlled without inducing pathology and it is resistant
to secondary infections with L. infantum [44]. It is pos-
sible that parasite persistence might mediate long-term
immunity in the liver in a similar manner to that seen
in the cutaneous leishmaniosis model caused by low-
dose infection with L. major [57].
Studying the granulomatous response is important
because granuloma development has been associated
with Leishmania infection in the liver, as demonstrated
in rodent models. Moreover, enhanced granuloma
maturation represents a good marker of successful vac-
cination against VL [58].
4.2. Spleen: visceralizing Leishmania parasites persist and
destroy the splenic architecture
In contrast to the liver, the spleen and bone marrow
become chronically infected in mice [44]. The immune
response to L. infantum in the spleen (Figure 6A-C) can
be separated into two phases: acute and chronic.
4.2.1. The acute phase of infection
Following intravenous experimental infection in mice, L.
infantum promastigotes enter the spleen via the splenic
artery and are rapidly removed from the circulation in
the spleen by marginal zone (MZ) macrophages and
rarely by DCs. It is likely that the majority of DCs
acquire Leishmania antigens by phagocytosis of infected
Figure 5 The liver granuloma reaction after L. infantum infection. (A) The histology of the liver and cellular infiltrates in infected mice at 28
days pi (×40). Compare (A) with the detail in the lower right corner of the image (non-infected mice showing normal histological appearance,
×40). Liver granuloma evolution: (B) immature granulomas. Early parasitization of KCs (arrows) with initial cell recruitment (×400), at 14 days pi.
(C) Mature granuloma assembly at infected KCs, resulting in the attraction of lymphocytes and monocytes, at 28 days pi (×400). (D) Mature-
sterile granuloma, free of amastigotes, at 56 days pi (×200).
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Page 8 of 13Figure 6 A schematic view of the immune responses in the BALB/c mice spleens after experimental infection with L. infantum.( A )I n
the initial stage of infection, parasites from the blood invade macrophages and DCs into the splenic MZ. Also, DCs acquire parasite antigens in
the MZ and subsequently migrate to the PALS. (B) DCs produce IL-12 and present parasite antigens to T cells in the PALS. (C) Leishmania-specific
T-cells are activated in the PALS but a failure in the specific effector response prevents them from interacting with parasitized host cells in the
MZ. Finally, chronicity of infection occurs in the spleen. (D) The kinetics of parasite burden and loss of germinal centers in the spleen after
L. infantum infection. The progressive loss of splenic germinal centers increased with time. Thus, in the spleen, a site of chronic infection, the
high levels of depletion in the white pulp at 56 days pi correlated with the high Leishmania parasite burden.
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Within these cells, promastigotes replicate intracellularly
as amastigotes. In the spleen, MZ macrophages phago-
cytose > 95% of intravenously administered L. infantum
parasites, where > 50% of the initial parasite inoculum is
killed within 24 h of infection [48]. It appears that DCs
acquire parasite antigens within the MZ (Figure 6A) and
subsequently migrate to the periarteriolar lymphoid
sheath (PALS). Once in the PALS, DCs secrete IL-12
[60] and present parasite antigens to T and NK
cells, resulting in the activation of these effector cells
(Figure 6B). Interestingly, L. infantum infection stimu-
lates IL-12 production by splenic DCs within the PALS,
but not infected macrophages within the MZ [61].
As described above, evidence suggests that Leishmania-
specific T lymphocytes are primed in the spleen during
the acute stage of infection (< 4 weeks) and then
migrate to the liver to initiate a granulomatous response
[42,44,48,62].
4.2.2. The chronic phase of infection
During the chronic stage of infection (> 4 weeks) in the
spleen, failure to resolve L. infantum infection occurs
( F i g u r e6 C )a n dt h es p l e n i ca r c h i t e c t u r eb r e a k sd o w n .
There are at least three possible explanations for the
failure of the specific effector response [48]: (1) assum-
ing that the priming of T and NK cells by DCs occurs
a tt h eP A L S ,as i t et h a ti sa n a t o m i c a l l ys e g r e g a t e df r o m
the MZ, infected macrophages fail to produce chemoat-
tractants to bring effector cells into their vicinity. (2)
Infected macrophages are unable to activate intrinsic
leishmanicidal mechanisms following exposure to cyto-
kines and ligands from T and NK cells. It has been
reported that L. infantum-infected macrophages fail to
produce IL-12 and also have a reduced capacity to gen-
erate both ROIs and NO, which are important microbi-
cidal molecules for killing intracellular pathogens
[44,54,61]. (3) Failure in the development of the efficient
granulomatous immune effector response occurs in the
spleen. Together, the low expression levels of MHC
class II on L. infantum macrophages and their intrinsic
defects in the generation of an antileishmanial response
(see above), contribute to failure to form inflammatory
foci around infected MZ macrophages [48].
Any of these three possibilities may contribute to the
failure of the spleen to resolve murine VL. Paradoxically,
the spleen is an initial site for the generation of cell-
mediated immune responses, but ultimately becomes a
site of parasite persistence, with associated immuno-
pathological changes [44].
4.2.3. Pathological changes in the spleen
In the spleen, L. infantum parasite persistence is accom-
panied by a failure of granuloma formation, splenomegaly
and other pathological changes, such as the disruption
of splenic microarchitecture, including the disintegration
of the white pulp accompanied by the destruction of folli-
cular DCs, and the absence of germinal centres
[10,22,24,42,48,61,63]. Interestingly, there is evidence
that high levels of TNF mediate the destruction of MZ
macrophages, while IL-10 promotes impaired DC migra-
tion into T-cell areas with subsequent ineffective T-cell
priming [44]. Data from our laboratory showed that dur-
ing the acute stage of infection (< 4 weeks), parasite bur-
den and the level of splenic disruption increases with
time (Figure 6D). Previously, we have reported that the
intensity of lymphoid depletion can vary depending on
the initial inoculum size. Indeed, higher numbers of lym-
phoid-depleted BALB/c mice were observed when a
high-inoculum size was used compared with a low-inocu-
lum size [26]. In agreement with previous studies [44],
our findings revealed the progressive development of
splenic pathology in mice infected with L. infantum,
including disruption of tissue anatomy accompanied by
the loss of germinal centers (Figure 7).
5. Remarks and discussion
The experimental murine model of L. infantum infec-
tion mimics many of the features of canine and human
infections. Syrian hamsters also exhibit severe clinical
signs and symptoms that are similar to those observed
in naturally infected dogs and humans [23,24,36]. How-
ever, the absence of iNOS expression [10,28,31] and the
suppression of lymphoproliferative responses [64,65]
observed, lead us to argue that the hamster is a more
suitable model for pathological studies of VL than for
the evaluation of vaccine candidates. However, to date,
most researchers have elected to use the BALB/c mouse
model for investigating disease pathogenesis of VL, as
well as for vaccine studies [26,44,54,66-68]. In mice, the
susceptibility to visceralizing Leishmania species is
mainly determined by the Slc11a1 gene that encodes a
phagosomal component that confers the ability to con-
trol the early infection (as described above). Even so,
BALB/c mice, lacking this gene, are able to control the
infection at a later stage [42,69]. In this context, BALB/c
mice provide a better model of self-healing or subclini-
cal infection than of disseminated visceral disease [10].
Paciello et al. [36] reported that susceptible mouse
strains do not reproduce progressive disease as observed
in human active VL. Furthermore, the intensity of
pathological changes in the visceral organs of BALB/c
mice can vary depending on the initial inoculum size, as
described above. Indeed, we proposed that infecting
mice with a large inoculum constitutes a suitable model
for the study of the pathological changes of VL [26].
Infection with L. infantum, either intravenously or
intradermally, leads to organ-specific immune responses
that are important determinants of disease outcome in
BALB/c mice [10,48]. Apparently, the intravenous route
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sandfly [22]. However, during natural infection, the
blood-sucking action of the vector on the skin of the host
may result in both intravenous and intradermal adminis-
tration of the parasite [26]. Subsequently, parasites multi-
ply rapidly for the first few weeks in the liver. Curiously,
the spleen is the initial site of generation of specific T
effector cells with the ability to move to the liver. Once
in the liver, the development of cell-mediated immune
responses is essential for the clearance of L. infantum
parasites. In contrast, the spleen ultimately becomes the
site of parasite persistence [26,44,66,70], suggesting that
the spleen is more susceptible to L. infantum infection
than the liver [71]. Interestingly, the leishmanicidal effi-
cacy of hepatic granulomas is dependent on their degree
of maturation [26,51,56]. Therefore, determining the
degree of maturation of hepatic granulomas constitutes
an effective tool for selecting VL vaccine candidates and
for monitoring disease progression.
In summary, it is reasonable to suppose that under-
standing the development of acquired parasite-specific
immunity in the liver and the reasons for effector sple-
nic response failure in VL, may lead to the development
of effective strategies for parasite clearance in host target
organs during VL and new treatments for canine and
human leishmaniosis.
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